Related Experiment Video
Updated: Jun 20, 2025

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
Published on: February 16, 2024
Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients
Antoine Lafarge1, Thibault Dupont1, Emmanuel Canet2
1Service de Médecine Intensive et Réanimation and.
Insights
Critically ill allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) patients admitted to the ICU have a 90-day survival rate of 51.8%. Age, graft-versus-host disease, and need for vasopressors or mechanical ventilation are key mortality predictors.
Area of Science:
- Critical Care Medicine
- Hematology
- Transplantation Immunology
Background:
- Allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) recipients are often considered poor candidates for intensive care unit (ICU) management.
- This perception necessitates a closer examination of outcomes and mortality predictors in this vulnerable patient population.
Purpose of the Study:
- To investigate the outcomes and identify determinants of mortality in critically ill Allo-HSCT patients admitted to the ICU.
- To evaluate the 90-day mortality rate and associated risk factors in this cohort.
Main Methods:
- A large, multicenter retrospective cohort study involving 1,164 Allo-HSCT patients admitted to 14 French ICUs between January 1, 2015, and December 31, 2020.
- Data collection included patient demographics, clinical status at ICU admission, interventions received (mechanical ventilation, renal replacement therapy, vasopressors), and mortality outcomes.
Main Results:
- The overall ICU mortality was 26%, with 90-day, 1-year, and 3-year mortality rates of 48%, 63%, and 70%, respectively.
- Key independent predictors of 90-day mortality included older age (>56 years), time from Allo-HSCT to ICU admission (30-90 days), corticosteroid-refractory acute graft-versus-host disease, and need for vasopressors or mechanical ventilation.
- In patients requiring mechanical ventilation, mortality ranged from 39% to 100% based on the number of associated risk factors.
Conclusions:
- The majority of critically ill Allo-HSCT recipients, including those requiring mechanical ventilation, survive ICU stays, with a 90-day survival rate of 51.8%.
- A thorough assessment of goals of care is crucial for patients with two or more identified risk factors for mortality.
Abstract:
Rationale: Allogeneic hematopoietic stem-cell transplantation (Allo-HSCT) recipients are still believed to be poor candidates for ICU management. Methods: We investigated outcomes and determinants of mortality in a large multicenter retrospective cohort of Allo-HSCT patients admitted between January 1, 2015, and December 31, 2020, to 14 French ICUs. The primary endpoint was 90-day mortality. Measurements and Main Results: In total, 1,164 patients were admitted throughout the study period. At the time of ICU admission, 765 (66%) patients presented with multiple organ dysfunction, including acute respiratory failure in 40% (n = 461). The median sepsis-related organ failure assessment score was 6 (interquartile range, 4-8). Invasive mechanical ventilation, renal replacement therapy, and vasopressors were required in 438 (38%), 221 (19%), and 468 (41%) patients, respectively. ICU mortality was 26% (302 deaths). Ninety-day, 1-year, and 3-year mortality rates were 48%, 63%, and 70%, respectively. By multivariable analysis, age > 56 years (odds ratio [OR], 2.0 [95% confidence interval (CI), 1.53-2.60]; P < 0.001), time from Allo-HSCT to ICU admission between 30 and 90 days (OR, 1.68 [95% CI, 1.17-2.40]; P = 0.005), corticosteroid-refractory acute graft-versus-host disease (OR, 1.63 [95% CI, 1.38-1.93]; P < 0.001), need for vasopressors (OR, 1.9 [95% CI, 1.42-2.55]; P < 0.001), and mechanical ventilation (OR, 3.1 [95% CI, 2.29-4.18]; P < 0.001) were independently associated with 90-day mortality. In patients requiring mechanical ventilation, mortality rates ranged from 39% (no other risk factors for mortality) to 100% (four associated risk factors for mortality). Conclusions: Most critically ill Allo-HSCT recipients survive their ICU stays, including those requiring mechanical ventilation, with an overall 90-day survival rate reaching 51.8%. A careful assessment of goals of care is required in patients with two or more risk factors for mortality.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Regulation of Hematopoietic Stem Cells

